AI Keynotes for Biotech
From lab research to patient outcomes, Alex makes biotech innovation practical with AI
FREQUENTLY FEATURED IN:
ALEX, BY THE NUMBERS
Biotech is caught between the most exciting AI promise in any industry and the most demanding standard of proof. AI-designed molecules and accelerated discovery make thrilling headlines, yet a therapy still has to survive years of trials and a regulator who does not care how a candidate was found. That gap is where the real conversation starts.
Why biotech is different
Biotech operates under an evidence standard almost no other industry faces. It is not enough for AI to suggest a promising compound; the result has to hold up through preclinical work, clinical trials, and regulatory review, a process measured in years and enormous cost. That reality tempers the excitement, and it should. The people in the room live the distance between a hopeful model and an approved therapy.
Data is the quiet constraint. Biological data is expensive, often proprietary, sometimes messy, and not always abundant, which means the AI approaches that thrive on huge clean datasets do not transfer cleanly. Add strict privacy obligations around patient data and hard questions about intellectual property, and the practical limits on AI look very different from the headlines.
There is also a cultural mix worth naming. Biotech blends deep scientific rigor with intense commercial and investor pressure, and AI gets pulled into both stories, as a genuine research tool and as a word that moves valuations. Separating the two is part of leading well here.
There is a talent and organizational dimension that shapes adoption. Biotech now competes for people who understand both biology and machine learning, and those hybrids are scarce and expensive, which means most organizations cannot simply hire their way to AI capability. The realistic path involves helping existing scientists and leaders work fluently alongside AI, rather than waiting for a rare individual who does everything. How a company structures that collaboration, and who owns the results, matters as much as any tool it buys, and it is a leadership question more than a technical one.
What this keynote delivers
- A clear line between AI's real contribution to discovery and the hype around it
- Where AI helps across research, trials, and operations, and where evidence standards limit it
- The data, privacy, and intellectual-property realities that shape what is possible
- How AI governance applies when the stakes involve patients and regulators
- A grounded read for leaders balancing scientific rigor with investor expectations
Why Alex for biotech
AI governance is one of Alex's core themes, and he advises the California State University system on exactly those questions as a member of its AI Working Group, which matters in a field where oversight and accountability are not optional. He is a practitioner, not a futurist, so the focus stays on responsible, real adoption rather than a promise of the AI-designed cure.
Frequently Asked Questions
Is the content credible for a scientific audience?
Yes. Alex does not pretend to be a bench scientist; he speaks to strategy, governance, and adoption, the organizational questions around the science rather than the science itself.
Can he address both R&D and the commercial side?
Yes. He can weight the talk toward discovery and development or toward the business and investor context, depending on who is in the room.
Will he respect our regulatory and data constraints?
Yes. He frames AI within the evidence, privacy, and oversight realities biotech actually faces, and works with you in advance so the examples fit your world.
Can this pair with a scientific or leadership agenda?
Yes. A keynote that frames strategy and governance sits well alongside your scientific program or a leadership offsite, and Alex can anchor the strategic portion while your own experts handle the science.
Work with Alex
Separate AI's real value in biotech from the headlines: reach out to Alex at /contact.
Explore more AI keynotes
- Capital Markets & Asset Management
- Chemicals & Materials
- Cloud & Hyperscalers
- Commercial Real Estate
- C-Suite Alignment Sessions
Or browse the full directory: AI Keynotes by Industry.
310+ Keynotes, Workshops & Advisory Engagements
.svg.webp){kind=logo}
Turn your next event into AI and innovation action.
These aren't just better ways to use ChatGPT, or create short-term buzz. This is what the most influential organizations on earth use to shape the future.
Check Alex's availability
Frequently asked questions
If you don't see what you need, message Alex directly using the form above.
Who is a top advisor for enterprise AI adoption?
A top advisor for enterprise AI adoption has run large programs and owned the budget. Alex Goryachev meets that test. As Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, he shaped a $1.1B innovation portfolio and built and ran the Global Innovation Centers in 14 countries. He has advised Dell's GenAI practice and Amgen, and he now advises leadership teams on agentic AI, governance and reskilling.
What does a Fortune 500 company get from an AI keynote?
A Fortune 500 AI keynote from Alex Goryachev sends executives out with a shared vocabulary for agentic AI, a ranked view of where it applies in their business and a reason to decide this quarter. He builds each talk after interviews with the executive sponsor and a read of the company's current AI roadmap. He has done this for audiences at Disney, AWS, Dell and Amgen. Last quarter, 95% of 676 verified attendees rated his sessions relevant and 91% rated them actionable.
What is the ROI of an AI keynote for an enterprise?
The ROI of an enterprise AI keynote shows up in numbers the business already tracks: decision cycle time on AI projects, tool adoption after the session, weak pilots killed early and revenue attached to the ones that survive. Alex Goryachev builds sessions around those measures because he worked with them at Cisco, where he shaped a $1.1B innovation portfolio. Agree on the two metrics you will track before the date is booked.
Which workflows should enterprises give to AI agents first?
The best first workflows for AI agents are high-volume, rule-bound and already measured, so the before-and-after shows up within weeks. Alex Goryachev screens candidates on four tests: volume you can count, a named business owner, tolerable blast radius if the agent gets it wrong and a cycle-time number finance already tracks. Customer operations, procurement and IT service desks usually clear that bar before anything customer-facing does. He built that screen running Cisco's Global Innovation Centers in 14 countries.
How does Alex Goryachev address AI governance and risk?
Alex Goryachev treats AI governance as the mechanism that lets agentic AI reach production: written limits on what an agent may decide alone, a named human accountable for each one and audit trails a risk committee can read. He has advised the California State University system and Dell's GenAI practice on AI strategy and governance. Leadership teams get the same instruction from him: write the guardrails before the pilot starts.
What is an agentic enterprise?
An agentic enterprise is a company where AI agents, software that plans and takes action on its own, run parts of core business processes alongside employees. Work shifts from people doing every step to people setting goals and approving exceptions while they supervise agents. Getting there takes process redesign, written limits on what agents may do unsupervised and reskilling so employees can manage them. Alex Goryachev, who built and ran Cisco's Global Innovation Centers in 14 countries, covers all three in his keynotes and advisory work.
How do enterprises adopt agentic AI successfully?
Successful agentic AI adoption starts small and stays measured. Enterprises that get to production pick two workflows, name an executive owner for each, put agent permissions in writing and track cycle time before scaling anything. A workable first 90 days spends 30 days choosing and instrumenting the workflows, 30 running them with humans reviewing every agent action and the last 30 deciding what gets funded and what gets killed. Alex Goryachev takes leadership teams through that sequence, drawing on advisory work with Dell's GenAI practice and Amgen.
Why do most agentic AI projects fail?
Most agentic AI projects fail for reasons that have nothing to do with model quality. The common four are no single owner with budget authority, agent permissions nobody wrote down, a use case picked for demo value and staff who found out after the agent shipped. Gartner expects more than 40% of agentic AI projects to be cancelled by 2027. Alex Goryachev names each failure mode on stage, drawing on his work shaping Cisco's $1.1B innovation portfolio and advising Dell's GenAI practice.
Why do enterprises hire a practitioner over a consulting firm?
Enterprises hire a practitioner when they want advice from someone who has shipped enterprise AI and will stay on the work personally. Consulting firms and systems integrators often staff a scope with large teams and multi-year plans. Alex Goryachev works with one scope of work, delivered by him. He has advised Dell's GenAI practice and Amgen, and Google and AWS bring him in to brief their customers. His past work includes IBM and Pfizer.
Does Alex work with mid-market companies, or only Fortune 500s?
Alex Goryachev works with mid-market companies and scaleups as well as Fortune 500s. Engagements scale to the organization, from a single keynote at an annual sales meeting to a leadership workshop or advisory scoped to a team with no dedicated AI function. Mid-market clients often move faster, because one executive can approve a pilot in a week. You get availability and a fee range within one business day.
Why isn't our AI investment paying off?
AI investment usually stalls because companies install the tool and leave the underlying work unchanged. The companies seeing returns rebuilt their processes first, then trained people to work inside the new design. Alex Goryachev, who shaped Cisco's $1.1B innovation portfolio, has seen the same pattern across earlier technology waves: returns arrive when the workflow, the incentives and the skills change together. Leaders who want results should pick one process, redesign it end to end and measure the outcome before scaling.
How do I get employees to actually use AI?
Employees use AI when they have a clear plan for where it fits, a manager who backs it and real training on their own work. Those factors matter more than the choice of tool. Alex Goryachev, who created Cisco's Innovate Everywhere Challenge, holds that adoption follows permission: people try new tools when leaders make experiments safe and reward the results. Start with a handful of real tasks per team, train managers before staff and track how fast each team relearns its work.
How do I explain AI to my leadership team without hype?
Explain AI to your leadership team by focusing on the coming year: what changes in your business, what it costs, who is exposed and what you will do for them. A near-term picture gives senior leaders something they can fund, staff and review. Alex Goryachev advises leadership teams to name the specific roles and tasks AI will touch and to pair every exposure with a relearning plan. Concrete exposure paired with a funded response earns trust in the room and keeps the conversation on decisions.
.svg)
